The landscape of cancer research and cancer care in China

IF 58.7 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Nature Medicine Pub Date : 2023-12-12 DOI:10.1038/s41591-023-02655-3

Zhihao Lu, Yang Chen, Dan Liu, Xi Jiao, Chang Liu, Yakun Wang, Zizhen Zhang, Keren Jia, Jifang Gong, Zhimin Yang, Lin Shen

{"title":"The landscape of cancer research and cancer care in China","authors":"Zhihao Lu, Yang Chen, Dan Liu, Xi Jiao, Chang Liu, Yakun Wang, Zizhen Zhang, Keren Jia, Jifang Gong, Zhimin Yang, Lin Shen","doi":"10.1038/s41591-023-02655-3","DOIUrl":null,"url":null,"abstract":"The rising cancer incidence rate in China poses a substantial public health concern, although there have been remarkable improvements in the country’s cancer mortality and survival rates. In this Review, we outline the current landscape and future directions of cancer care and research in China. We discuss national screening programs and strategies for cancer detection and delve into the evolving landscape of cancer care, emphasizing the adoption of multidisciplinary, comprehensive treatment and precision oncology. Additionally, we examine changes in drug research and development policies that have enabled approval of new drugs. Finally, we look to the future, highlighting key priorities and identifying gaps. Effectively addressing challenges and seizing opportunities associated with cancer research in China will enable the development of targeted approaches to alleviate the global burden of cancer. The authors discuss how screening strategies, treatment approaches and precision oncology are evolving in China and outline trends and priorities in the drug development and regulatory landscape.","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"29 12","pages":"3022-3032"},"PeriodicalIF":58.7000,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41591-023-02655-3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The rising cancer incidence rate in China poses a substantial public health concern, although there have been remarkable improvements in the country’s cancer mortality and survival rates. In this Review, we outline the current landscape and future directions of cancer care and research in China. We discuss national screening programs and strategies for cancer detection and delve into the evolving landscape of cancer care, emphasizing the adoption of multidisciplinary, comprehensive treatment and precision oncology. Additionally, we examine changes in drug research and development policies that have enabled approval of new drugs. Finally, we look to the future, highlighting key priorities and identifying gaps. Effectively addressing challenges and seizing opportunities associated with cancer research in China will enable the development of targeted approaches to alleviate the global burden of cancer. The authors discuss how screening strategies, treatment approaches and precision oncology are evolving in China and outline trends and priorities in the drug development and regulatory landscape.

Abstract Image

查看原文本刊更多论文

中国癌症研究和癌症治疗的现状

尽管中国的癌症死亡率和存活率有了显著提高，但癌症发病率的上升仍是一个重大的公共卫生问题。在这篇综述中，我们概述了中国癌症治疗和研究的现状和未来发展方向。我们讨论了癌症检测的国家筛查计划和策略，并深入探讨了不断发展的癌症治疗格局，强调了多学科综合治疗和精准肿瘤学的采用。此外，我们还探讨了促使新药获批的药物研发政策的变化。最后，我们展望未来，强调关键优先事项并找出差距。有效应对与中国癌症研究相关的挑战并抓住机遇，将有助于开发有针对性的方法，减轻全球癌症负担。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Medicine 医学-生化与分子生物学

CiteScore

100.90

自引率

0.70%

发文量

525

审稿时长

1 months

期刊介绍： Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors. Nature Medicine consider all types of clinical research, including: -Case-reports and small case series -Clinical trials, whether phase 1, 2, 3 or 4 -Observational studies -Meta-analyses -Biomarker studies -Public and global health studies Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.